Sanofi (@sanofi) / Twitter
Inside Sanofi's General Medicines Unit: Embracing A New Commercial Model :: In Vivo
Sanofi pumps $750M into VC unit to push deeper into biotech investing | Fierce Biotech
GI toxicity hits midstage Sanofi GLP-1 drug as patients drop out | Fierce Biotech
Exclusive: Sanofi to let go of staff at vaccine plants in India as part of review | Reuters
Home - Sanofi U.S.
Sanofi launches global health brand with non-profit treatments | Reuters
Diabetes Drug Giant Sanofi Cuts Insulin Prices by Up to 78% - WSJ
Sanofi | Paris
Sanofi launches Impact® brand of medicines for low-income countries
Technip Energies | Projects | Sanofi Algeria pharmaceutical production plant | Largest pharmaceutical production plant in Africa
Sanofi Bolsters Diabetes Position with $2.9B Provention Buyout | BioSpace
Former Sanofi CEO Brandicourt takes board seat at RNAi therapy maker Alnylam | Fierce Pharma
Sanofi Agrees to Pay $2.9 Billion For Provention Bio
Sanofi, AZ's RSV contender nears first global approval
A history of Sanofi
Sanofi to cut US price of its most-prescribed insulin by 78% | Reuters
About us - Sanofi
Sanofi dumps Principia Biopharma's San Francisco labs with plans to immediately cut 38 jobs | Fierce Biotech
Sanofi expanding Fabrazyme plant in MA
Regeneron and Sanofi Look for Billions From COPD Drug - WSJ
